T0	Participants 75 123	children and adolescents with autistic disorder.
T1	Participants 276 325	children and adolescents with autistic disorders.
T2	Participants 394 494	patients (5-17 years of age, who completed the previous fixed-dose, 6 week, double-blind [DB] phase)
T3	Participants 771 841	RESULTS Fifty-six (71%) out of 79 enrolled patients completed the OLE;